Zhang 2018d.

Methods	Study design: Randomised clinical trial Study duration: July 2013 to April 2014 Duration of follow‐up: 3 months Setting: Hospital
Participants	Age (mean ± SD, range): 52.6 ± 7.2 years, 31‐80 years Male (n/total): 49/86 Tumour diameter (mean ± SD, range): 3.8 ± 0.6, 3‐5 cm Child‐Pugh Class (patients): Class A: 52; Class B: 34
Interventions	TACE + MWA group (n = 43): TACE: Chemotherapeutic drugs: 5‐fluorouracil, theprubicin, and epirubicin. Two sessions of TACE treatment were performed for each patient, with an interval of 4 weeks. MWA: The interval between TACE and RFA was 2 weeks. Output power of 60‐90 W TACE group (n = 43): Chemotherapeutic drugs: 5‐fluorouracil, theprubicin, and epirubicin. Two sessions of TACE treatment were performed for each patient, with an interval of 4 weeks.
Outcomes	Serum level of AST and ALT Serum level of AFP Tumour response, measured by ultrasound or CT, assessed by the reduction of tumour diameter Adverse events
Notes	Country of study: China Source of funding: None There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.